-DOCSTART- -X- O
BACKGROUND -X- _ O
: -X- _ O
Acute -X- _ O
lower -X- _ O
respiratory -X- _ O
tract -X- _ O
infections -X- _ O
( -X- _ O
ALRTIs -X- _ O
) -X- _ O
account -X- _ O
for -X- _ O
most -X- _ O
antibiotics -X- _ O
prescribed -X- _ O
in -X- _ O
primary -X- _ O
care -X- _ O
despite -X- _ O
lack -X- _ O
of -X- _ O
efficacy -X- _ O
, -X- _ O
partly -X- _ O
due -X- _ O
to -X- _ O
clinician -X- _ O
uncertainty -X- _ O
about -X- _ O
aetiology -X- _ O
and -X- _ O
patient -X- _ O
concerns -X- _ O
about -X- _ O
illness -X- _ O
course. -X- _ O
Nucleic -X- _ O
acid -X- _ O
amplification -X- _ O
tests -X- _ O
could -X- _ O
assist -X- _ O
antibiotic -X- _ O
targeting. -X- _ O
METHODS -X- _ O
: -X- _ O
In -X- _ O
this -X- _ O
prospective -X- _ O
cohort -X- _ O
study -X- _ O
, -X- _ O
645 -X- _ B-Patient
patients -X- _ I-Patient
presenting -X- _ I-Patient
to -X- _ I-Patient
primary -X- _ I-Patient
care -X- _ I-Patient
with -X- _ I-Patient
acute -X- _ I-Patient
cough -X- _ I-Patient
and -X- _ I-Patient
suspected -X- _ I-Patient
ALRTI -X- _ I-Patient
, -X- _ O
provided -X- _ O
throat -X- _ O
swabs -X- _ O
at -X- _ O
baseline. -X- _ O
These -X- _ O
were -X- _ O
tested -X- _ O
for -X- _ O
respiratory -X- _ O
pathogens -X- _ O
by -X- _ O
real-time -X- _ O
polymerase -X- _ O
chain -X- _ O
reaction -X- _ O
and -X- _ O
classified -X- _ O
as -X- _ O
having -X- _ O
a -X- _ O
respiratory -X- _ O
virus -X- _ O
, -X- _ O
bacteria -X- _ O
, -X- _ O
both -X- _ O
or -X- _ O
neither. -X- _ O
Three -X- _ O
hundred -X- _ O
fifty-four -X- _ O
participants -X- _ O
scored -X- _ O
the -X- _ B-Outcome
symptoms -X- _ I-Outcome
severity -X- _ I-Outcome
daily -X- _ I-Outcome
for -X- _ I-Outcome
1 -X- _ I-Outcome
week -X- _ I-Outcome
in -X- _ I-Outcome
a -X- _ I-Outcome
diary -X- _ I-Outcome
( -X- _ I-Outcome
0 -X- _ I-Outcome
= -X- _ I-Outcome
absent -X- _ I-Outcome
to -X- _ I-Outcome
4 -X- _ I-Outcome
= -X- _ I-Outcome
severe -X- _ I-Outcome
problem -X- _ I-Outcome
) -X- _ I-Outcome
. -X- _ I-Outcome
RESULTS -X- _ I-Outcome
: -X- _ I-Outcome
Organisms -X- _ I-Outcome
were -X- _ I-Outcome
identified -X- _ I-Outcome
in -X- _ I-Outcome
346 -X- _ I-Outcome
/ -X- _ I-Outcome
645 -X- _ I-Outcome
( -X- _ I-Outcome
53.6 -X- _ I-Outcome
% -X- _ I-Outcome
) -X- _ I-Outcome
participants. -X- _ I-Outcome
There -X- _ I-Outcome
were -X- _ I-Outcome
differences -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
prevalence -X- _ I-Outcome
of -X- _ I-Outcome
seven -X- _ I-Outcome
symptoms -X- _ I-Outcome
between -X- _ I-Outcome
the -X- _ I-Outcome
organism -X- _ I-Outcome
groups -X- _ I-Outcome
at -X- _ I-Outcome
baseline. -X- _ I-Outcome
Those -X- _ I-Outcome
with -X- _ I-Outcome
a -X- _ I-Outcome
virus -X- _ I-Outcome
alone -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
those -X- _ I-Outcome
with -X- _ I-Outcome
both -X- _ I-Outcome
virus -X- _ I-Outcome
and -X- _ I-Outcome
bacteria -X- _ I-Outcome
, -X- _ I-Outcome
had -X- _ I-Outcome
higher -X- _ I-Outcome
average -X- _ I-Outcome
severity -X- _ I-Outcome
scores -X- _ I-Outcome
of -X- _ I-Outcome
all -X- _ I-Outcome
symptoms -X- _ I-Outcome
combined -X- _ I-Outcome
during -X- _ I-Outcome
the -X- _ I-Outcome
week -X- _ I-Outcome
of -X- _ I-Outcome
follow-up -X- _ I-Outcome
than -X- _ I-Outcome
those -X- _ I-Outcome
in -X- _ I-Outcome
whom -X- _ I-Outcome
no -X- _ I-Outcome
organisms -X- _ I-Outcome
were -X- _ I-Outcome
detected -X- _ I-Outcome
[ -X- _ I-Outcome
adjusted -X- _ I-Outcome
mean -X- _ I-Outcome
differences -X- _ I-Outcome
0.204 -X- _ I-Outcome
( -X- _ I-Outcome
95 -X- _ I-Outcome
% -X- _ I-Outcome
confidence -X- _ I-Outcome
interval -X- _ I-Outcome
0.010 -X- _ I-Outcome
to -X- _ I-Outcome
0.398 -X- _ I-Outcome
) -X- _ I-Outcome
and -X- _ I-Outcome
0.348 -X- _ I-Outcome
( -X- _ I-Outcome
0.098 -X- _ I-Outcome
to -X- _ I-Outcome
0.598 -X- _ I-Outcome
) -X- _ I-Outcome
, -X- _ I-Outcome
respectively -X- _ I-Outcome
] -X- _ I-Outcome
. -X- _ I-Outcome
There -X- _ I-Outcome
were -X- _ I-Outcome
no -X- _ I-Outcome
differences -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
duration -X- _ I-Outcome
of -X- _ I-Outcome
symptoms -X- _ I-Outcome
rated -X- _ I-Outcome
as -X- _ I-Outcome
moderate -X- _ I-Outcome
or -X- _ I-Outcome
severe -X- _ I-Outcome
between -X- _ I-Outcome
organism -X- _ I-Outcome
groups. -X- _ I-Outcome
CONCLUSIONS -X- _ O
: -X- _ O
Differences -X- _ O
in -X- _ O
presenting -X- _ O
symptoms -X- _ O
and -X- _ O
symptoms -X- _ O
severity -X- _ O
can -X- _ O
be -X- _ O
identified -X- _ O
between -X- _ O
patients -X- _ O
with -X- _ O
viruses -X- _ O
and -X- _ O
bacteria -X- _ O
identified -X- _ O
on -X- _ O
throat -X- _ O
swabs. -X- _ O
The -X- _ O
magnitude -X- _ O
of -X- _ O
these -X- _ O
differences -X- _ O
is -X- _ O
unlikely -X- _ O
to -X- _ O
influence -X- _ O
management. -X- _ O
Most -X- _ O
patients -X- _ O
had -X- _ O
mild -X- _ O
symptoms -X- _ O
at -X- _ O
7 -X- _ O
days -X- _ O
regardless -X- _ O
of -X- _ O
aetiology -X- _ O
, -X- _ O
which -X- _ O
could -X- _ O
inform -X- _ O
patients -X- _ O
about -X- _ O
likely -X- _ O
symptom -X- _ O
duration -X- _ O
. -X- _ O

